Loading
Helus Pharma Inc. Stock: price and insider trades · United States
US·Mcap US$758.5M
1 insider bought €34k of shares over the last 90 days, the latest filed 01 Oct 2026.
Helus Pharma Inc.: what insiders have been doing
Helus Pharma Inc. is a listed company. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 3 filings signed by 3 insiders.
Only purchases show up on the open market, 1 purchase in all worth €34k, filed by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a purchase of €34k from Cavers Greg, disclosed on 1 October 2026. On the buying side, the filings list 1 finance chief among the declarants.
The last insider purchase was made public on 1 October 2026, 17 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 3 filings, this issuer sits below that mark. Over the whole record (from 2026), the tally stands at 1 purchase and no sales.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
3
Thresholds
n/a
Buy Volume
€34,059
1 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleGreg Cavers1 buy
Analyst consensus: bullish or bearish?
Analysts rate Helus Pharma Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$40.21.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended March 2026 · cache
US$10.38
Analyst consensus
10 analystsStrong buy
US$14.92Target US$40.21(+287%)US$70.21
Income statement
EBITDA-US$142.5M
Net income-US$148M0.0% margin
Valuation
PER (forward)-4.1x
P/Book2.7x
Beta0.54
Balance sheet & cash
Market capUS$758.5M
Free Cash Flow-US$134.6M
Profitability & ownership
ROE-86.9%
ROA-44.4%
% insiders12.9%
% institutions41.3%
Last declaration on 1 October 2026
Declarations3 total
248,000 sharesCommon SharesSEC:0000912282-26-001332:0
3,000 shares@ US$12.91100.0% of flowCommon SharesSEC:0000912282-26-001334:0
Canonical exit: 28 Dec 2026 (T+90)
248,000 sharesCommon SharesSEC:0000912282-26-001335:0
3 of 3 declarations
About Helus Pharma Inc.
Helus Pharma Inc. is a pharmaceutical company focused on developing innovative treatments. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
